Key Takeaways GLP-1 receptor agonists, including Tirzepatide, Semaglutide, and Liraglutide, are effective in promoting weight loss and improving glycemic control, with varying degrees of effectiveness and administration schedules
Neurogastroenterol Motil 2010;22:664-e203.ArticlePubMed 26
Wellness Works
Connections between metabolic disorders and skin diseases such as Pso and HS lead to varying effects of GLP-1RAs based on individual immune reactions [18]
With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting, said Kenneth Custer, executive vice president of Eli Lilly and president of Lilly Cardiometabolic Health, in a statement from the company
a few had intense nausea each time they went up a dose, sometimes so bad they were bedridden for a day